Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2014

01-07-2014 | Review

Gastrointestinal Mucositis: The Role of MMP-Tight Junction Interactions in Tissue Injury

Authors: Noor Al-Dasooqi, Hannah R. Wardill, Rachel J Gibson

Published in: Pathology & Oncology Research | Issue 3/2014

Login to get access

Abstract

Chemotherapy for cancer causes significant gut toxicity known as mucositis. The pathogenesis of mucositis is ill defined. Recent clinical research guidelines have highlighted epithelial junctional complexes as emerging targets within mucositis research. Given the robust biological evidence linking tight junctions and matrix metalloproteinases, key mediators of mucositis, tight junction proteins have received significant attention. Despite this, the link between tight junctions, matrix metalloproteinases and mucositis development is yet to be established. This critical review therefore aims to describe the role of matrix metalloproteinases in mucositis, and how matrix metalloproteinase-dependent tight junction disruption may contribute to the pathobiology of mucositis.
Literature
1.
Keefe D, Schubert M et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef
2.
3.
Sonis S, Shklar T et al (1990) An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69:437–443PubMedCrossRef
4.
Paris F, Fuks Z et al (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293–297PubMedCrossRef
5.
Logan R, Stringer A et al (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63:239–251PubMedCrossRef
6.
Stringer A, Gibson R et al (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90:489–499PubMedCentralPubMedCrossRef
7.
Stringer A, Gibson R et al (2009) Chemotherapy-induced changes to microflora: evidence and implications of change. Curr Drug Metab 10:79–83PubMedCrossRef
8.
Al-Dasooqi N, Bowen J et al (2011) Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. Int J Exp Pathol 92:357–365PubMedCentralPubMedCrossRef
9.
Al-Dasooqi N, Gibson R et al (2010) Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the DA rat. Exp Biol Med 235:1244–1256CrossRef
10.
Ma T, Iwamoto G et al (2004) TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 286:G367–G376PubMedCrossRef
11.
Blijlevens NM, Donnelly JP, de Pauw BE (2005) Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant 35(7):707–711PubMedCrossRef
12.
Walsh-Reitz M, Huang E et al (2005) AMP-18 protects barrier function of colonic epithelial cells: role of tight junction proteins. Am J Physiol Gastrointest Liver Physiol 289:G163–G171PubMedCentralPubMedCrossRef
13.
Wardill H, Bowen J, Gibson R (2013) Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol 70:627–635CrossRef
14.
Hollander D (1999) Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep 1:410–416PubMedCrossRef
15.
Gonzalez-Mariscal L, Tapia R, Chamorro D (2008) Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 1778(3):729–756PubMedCrossRef
16.
Keefe D, Cummins AG et al (1997) Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci 92:385–389PubMed
17.
18.
Hamada K, Shitara Y et al (2010) Zonula Occluden-1 alterations and enhances intestinal permeability in methotrexate-treated rats. Cancer Chemother Pharmacol 66:1031–1038PubMedCrossRef
19.
Nakao T, Kurita N et al (2012) Irinotecan injures tight junction and causes bacterial translocation in rat. J Surg Res 173(2):341–347PubMedCrossRef
20.
Youmba SB, Belmonte L et al (2011) Methotrexate Modulates Tight Junctions Through NF-kappaB, MEK and JNK Pathways. J Pediatr Gastroenterol Nutr
21.
Stringer A, Al-Dasooqi N et al (2013) Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer. [Epub ahead of print]
22.
Sengupta N, MacDonald T (2007) The role of matrix metalloproteinases in stromal/epithelial interactions in the gut. Physiology 22:401–409PubMedCrossRef
23.
Clark I, Swingler T et al (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40:1362–1378PubMedCrossRef
24.
25.
Wolf M, Albrecht S, Marki C (2008) Proteolytic processing of Chemokines: implications in physiological and pathological conditions. Int J Biochem Cell Biol 40:1185–1198PubMedCrossRef
26.
27.
Chakraborti S, Mandal M et al (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269–285PubMedCrossRef
28.
Pender S, MacDonald T (2004) Matrix metalloproteinases and the gut- new roles for old enzymes. Curr Opin Pharmacol 4:546–550PubMedCrossRef
29.
Van Wart H, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 87:5578–5582PubMedCentralPubMedCrossRef
30.
Dhaouadi T, Sfar I et al (2007) Role of immune system, apoptosis and angiogenesis in pathogenesis of rheumatoid arthritis and joint destruction, a systematic review. Tunis Med 85:991–998PubMed
31.
Sorsa T, Tjaderhane L et al (2006) Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 38:306–321PubMedCrossRef
32.
Vandenbroucke R, Dejonckheere E, and Libert C (2011) A therapeutic role for MMP inhibitors in lung diseases? Eur Respir J [Epub ahead of print]
33.
Parks W, Wilson C, Lopez-Boado Y (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617–629PubMedCrossRef
34.
Shipley J, Wesselschmidt R et al (1996) Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci 93:3942–3946PubMedCentralPubMedCrossRef
35.
36.
Lanone S, Zheng T et al (2002) Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest 110:463–474PubMedCentralPubMedCrossRef
37.
Itoh T, Matsuda H et al (2002) The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 169:2643–2647PubMedCrossRef
38.
Mudgett J, Hutchinson N et al (1998) Susceptability of stromelysin-1 deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 41:110–121PubMedCrossRef
39.
Corry D, Rishi K et al (2002) Decreased allergic lung inflammatory cell egression and increased susceptability to asphyxiation in MMP2-deficiency. Nat Immunol 3:347–353PubMedCentralPubMedCrossRef
40.
Hartzell W, Shapiro S (1999) Marcophage elastase prevents Gemella morbillorum infection and improves outcome following murine bone marrow transplantation. Chest 116:31S–32SPubMedCrossRef
41.
Burke B (2004) The role of matrix metalloproteinase 7 in innate immunity. Immunobiology 209:51–56PubMedCrossRef
42.
43.
Will C, Fromm M, Muller D (2008) Claudin tight junction proteins: novel aspects in paracellular transport. Perit Dial Int J Int Soc Perit Dial 28(6):577–584
44.
Anderson JM, Balda MS, Fanning AS (1993) The structure and regulation of tight junctions. Curr Opin Cell Biol 5(5):772–778PubMedCrossRef
45.
Fanning AS, Anderson JM (2009) Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of cellular junctions. Ann N Y Acad Sci 1165:113–120PubMedCentralPubMedCrossRef
46.
Katsuno T, Umeda K et al (2008) Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. Mol Biol Cell 19(6):2465–2475PubMedCentralPubMedCrossRef
47.
48.
Umeda K, Ikenouchi J et al (2006) ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 126(4):741–754PubMedCrossRef
49.
Bertiaux-Vandaele N, Youmba SB et al (2011) The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 106(12):2165–2173PubMedCrossRef
50.
Schulzke JD, Ploeger S et al (2009) Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 1165:294–300PubMedCrossRef
51.
Turner J (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9:799–809PubMedCrossRef
52.
53.
Schulzke JD, Gitter AH et al (2005) Epithelial transport and barrier function in occludin-deficient mice. Biochim Biophys Acta 1669(1):34–42PubMedCrossRef
54.
Ulluwishewa D, Anderson RC et al (2011) Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 141(5):769–776PubMedCrossRef
55.
Fazeny-Dorner B, Veitl M et al (2002) Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). Cancer Chemother Pharmacol 49(4):294–298PubMedCrossRef
56.
Wardill H, Bowen J and Gibson R (2013) Irinotecan disrupts tight junction protein occludin in the rat small intestine, in Multinational Association for Supprotive Care in Cancer. J Support Care Cancer. Berlin, Germany
57.
Bauer A, Burgers H et al (2010) Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab 30:837–848PubMedCentralPubMedCrossRef
58.
Lischper M, Beuck S et al (2010) Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions. Brain Res 1326:114–127PubMedCrossRef
59.
Vermeer P, Denker J et al (2009) MMP9 modulates tight junction integrity and cell viability in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 296:L751–L762PubMedCentralPubMedCrossRef
60.
Blecharz K, Haghikia A et al (2010) Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult Scler 16:293–302PubMedCrossRef
61.
Liu W, Hendren J et al (2009) Normobaric hyperoxia attenuates early blood–brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 108:811–820PubMedCentralPubMedCrossRef
62.
Chen W, Hartman R, Ayer R, Marcantonio S, Kamper J, Tang J, Zhang JH (2009) Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem 111:726–736PubMedCrossRef
63.
Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, Ding JY, Dornbos D 3rd, Li X, Guthikonda M, Rossi NF, Ding Y (2011) The role of hypoxia-inducible factor-1alpha, aquaporin-4 and matrix metalloproteinase-9 in blood–brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg 114:92–101PubMedCrossRef
64.
Siu M, Lee W, Cheng C (2003) The interplay of collagen IV, tumor necrosis factor-alpha, gelatinase B (matrix metalloprotease-9), and tissue inhibitor of metalloproteases-1 in the basal lamina regulates Sertoli cell-tight junction dynamics in the rat testis. Endocrinology 144:371–387PubMedCrossRef
65.
Gorodeski G (2007) Estrogen decrease in tight junction resistance involves matrix metalloproteinase-7-mediated remodeling of occludin. Endocrinology 148:218–231PubMedCentralPubMedCrossRef
66.
Jeong S, Ledee D et al (2012) Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation. Am J Pathol 180:2028–2039PubMedCentralPubMedCrossRef
Metadata
Title
Gastrointestinal Mucositis: The Role of MMP-Tight Junction Interactions in Tissue Injury
Authors
Noor Al-Dasooqi
Hannah R. Wardill
Rachel J Gibson
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-013-9733-y

Other articles of this Issue 3/2014

Pathology & Oncology Research 3/2014 Go to the issue

Research

Clinicopathological and Molecular Spectrum of Ewing Sarcomas/PNETs, Including Validation of EWSR1 Rearrangement by Conventional and Array FISH Technique in Certain Cases

Research

Prognostic Significance of Cyclin D1 and E-cadherin Expression in Laryngeal Squamous Cell Carcinoma

Research

Prognostic Value of Podoplanin Expression in Oral Squamous Cell Carcinoma―A Regression Model Auxiliary to UICC Classification

Research

TPX2 Overexpression in Medullary Thyroid Carcinoma Mediates TT Cell Proliferation

Research

Reversing Multidrug-Resistant by RNA Interference Through Silencing MDR1 Gene in Human Hepatocellular Carcinoma Cells Subline Bel-7402/ADM

Research

Fuzzy Clustering Analysis of Osteosarcoma Related Genes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits